Primoris Services had a return on equity of 15.23% and a net margin of 2.68%. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.58 billion.

Ratings for Primoris Services (NYSE:PRIM) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

J.P. Morgan analyst Drew Chamberlain maintained a Buy rating on Primoris Services (PRIM – Research Report) today and set a price target of $88.00. The company’s shares closed yesterday at $69.06.

Even as someone who cooks the vast majority of meals at home and goes through a lot of olive oil every week, I find that section of the grocery store overwhelming. Some hail from Greece ...

Research on the effects of olive oil for eczema is mixed. Some studies suggest it may help relieve inflammation and pain, while others found that it may damage the skin barrier and worsen symptoms.

By 1997, when 84 countries signed the Kyoto Protocol to curb global greenhouse gas emissions, the oil industry had built an effective apparatus for actively discrediting climate science and ...

Oil stocks are often volatile, influenced by geopolitics and supply-demand imbalances. Investments in oil stocks should focus on companies with strong financial health and low operation costs ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...